Spectrum Pharmaceuticals (NASDAQ:SPPI) is a company with over 16 ongoing clinical trials, seven of which will soon be reporting pivotal results. SPPI's pipeline breadth is a double-edged sword. A bloated pipeline can be difficult to manage and focus, but the diversity and innovation inherent in SPPI's pipeline increases the potential that the company might hit something big. The company has some unique therapeutics with little to no direct competition. Several of these therapeutics are approved and being sold to treat niche/orphan markets, giving SPPI the opportunity to price high. The company has various partnerships for both development and marketing: Pfizer/Takeda for Fusilev, Bayer for Zevalin, Topotarget for Belinostat and Allergan for Apaziquone. Moreover, OncoRx is a subsidiary...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|